PI
PTCT icon

PEAK6 Investments’s PTC Therapeutics PTCT Stock Holding History

PEAK6 Investments’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,600
Closed -$55K – 4480
2018
Q4 		$55K Hold
1,600
– – ﹤0.01% 3611
2018
Q3 		$75K Buy
+1,600
New +$66.2K ﹤0.01% 3634

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PEAK6 Investments's PTCT Position: Q4 2020 in Review

PEAK6 Investments sold out of PTC Therapeutics (PTCT) in Q4 2020, closing a stake of 447 shares — an estimated $21K sold.

PEAK6 Investments first reported a position in PTCT in Q3 2018 and held it in 9 quarters. The position peaked at $620K in Q4 2018. 215 funds tracked by Wall St. Rank hold PTCT as of Q4 2020.

  • PEAK6 Investments reported no remaining PTC Therapeutics position as of Q4 2020 after selling out during the quarter.
  • PEAK6 Investments sold 447 PTC Therapeutics shares in Q4 2020, an estimated $21K.
  • PEAK6 Investments first reported a position in PTC Therapeutics in Q3 2018 and held it in 9 quarters.
  • PEAK6 Investments's PTC Therapeutics position peaked at $620K in Q4 2018.
  • 215 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2020.

Based on PEAK6 Investments's 13F filing for Q4 2020, filed 12 Feb 2021.